NCT07020221 2026-03-09
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
Verastem, Inc.
Mirati Therapeutics Inc.
NKGen Biotech, Inc.
Array BioPharma
Merck KGaA, Darmstadt, Germany
Hadassah Medical Organization